Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_3
3
75%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

completed125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

NCT00741715
terminatedphase_3

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

NCT00718965
terminatedphase_3

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

NCT00766688
completedphase_2

A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia

NCT00440154

Clinical Trials (4)

Showing 4 of 4 trials
NCT00741715Phase 3

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Terminated
NCT00718965Phase 3

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Terminated
NCT00766688Phase 3

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

Terminated
NCT00440154Phase 2

A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4